CY1106635T1 - Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια - Google Patents

Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια

Info

Publication number
CY1106635T1
CY1106635T1 CY20071100731T CY071100731T CY1106635T1 CY 1106635 T1 CY1106635 T1 CY 1106635T1 CY 20071100731 T CY20071100731 T CY 20071100731T CY 071100731 T CY071100731 T CY 071100731T CY 1106635 T1 CY1106635 T1 CY 1106635T1
Authority
CY
Cyprus
Prior art keywords
immunoproduct
vaccines
peptide containing
formyl methionyl
formyl
Prior art date
Application number
CY20071100731T
Other languages
English (en)
Inventor
Jeannine Alexander
William I. Cox
Original Assignee
Connaught Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Technology Corporation filed Critical Connaught Technology Corporation
Publication of CY1106635T1 publication Critical patent/CY1106635T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ανοσολογικά ανοσοενισχυτικά που αποτελούνται από το Ν-φορμυλο μεθειονυλο πεπτίδιο fMLP. To fMLP, όταν χρησιμοποιείται ως ένα ανοσοενισχυτικό σε συμφωνία με την παρούσα εφεύρεση, φροντίζει για μία ανοσοαπόκριση σε υπο-βέλτιστες δόσεις των ανασυνδυασμένων αντιγόνων.
CY20071100731T 1998-12-18 2007-06-04 Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια CY1106635T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/216,702 US6017537A (en) 1998-12-18 1998-12-18 Formyl methionyl peptide vaccine adjuvant
PCT/US1999/030188 WO2000035482A2 (en) 1998-12-18 1999-12-17 Novel adjuvant for subunit or component vaccines

Publications (1)

Publication Number Publication Date
CY1106635T1 true CY1106635T1 (el) 2012-01-25

Family

ID=22808169

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100731T CY1106635T1 (el) 1998-12-18 2007-06-04 Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
CY20111100355T CY1111372T1 (el) 1998-12-18 2011-04-05 Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100355T CY1111372T1 (el) 1998-12-18 2011-04-05 Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο

Country Status (15)

Country Link
US (1) US6017537A (el)
EP (2) EP1800692B1 (el)
JP (1) JP2002532436A (el)
AT (2) ATE496630T1 (el)
AU (1) AU773697B2 (el)
CA (2) CA2342609C (el)
CY (2) CY1106635T1 (el)
DE (2) DE69943170D1 (el)
DK (2) DK1140166T3 (el)
ES (2) ES2284285T3 (el)
HK (1) HK1110769A1 (el)
NZ (1) NZ510544A (el)
PT (2) PT1800692E (el)
SI (2) SI1800692T1 (el)
WO (1) WO2000035482A2 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US20030050249A1 (en) * 2000-05-23 2003-03-13 Clagett James A. Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2464228C (en) * 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
WO2004027041A2 (en) 2002-09-19 2004-04-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU2003287267A1 (en) 2002-10-29 2004-05-25 Centro De Pesquisas Goncalo Moniz Lutzomyia longipalpis polypeptides and methods of use
JP2006526389A (ja) * 2003-01-07 2006-11-24 ニューロームド テクノロジーズ、インク． 蛍光ｔ型チャネルアッセイ
AU2005247298B8 (en) 2004-04-14 2011-03-10 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US7887522B2 (en) 2005-03-18 2011-02-15 The Procter And Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
EP1924282B1 (en) 2005-08-15 2017-01-11 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
CN101528263B (zh) * 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
EP2088979A2 (en) * 2006-12-04 2009-08-19 The Procter & Gamble Company Absorbent articles comprising graphics
EP2899203B1 (en) 2008-05-08 2019-07-10 Boehringer Ingelheim Animal Health USA Inc. Leishmania vaccine using sand fly salivary immunogen
US9400873B2 (en) 2011-12-21 2016-07-26 Deka Products Limited Partnership System, method, and apparatus for dispensing oral medications
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
LT2734230T (lt) 2011-07-20 2019-03-25 Merial Limited Rekombinantinė kačių leikemijos viruso vakcina, turinti optimizuotą kačių leukemijos viruso apvalkalo geną
DK2741740T3 (en) 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
CA2867893C (en) 2012-03-20 2022-09-20 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
MX2016014868A (es) 2014-05-14 2017-07-19 Merial Inc Metodos para secar por congelacion y rehidratar productos biologicos.
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20230009631A (ko) * 2021-07-09 2023-01-17 포항공과대학교 산학협력단 포밀 메티오닌 특이 항체 제조를 위한 신규한 항원 펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Also Published As

Publication number Publication date
DE69935866D1 (de) 2007-05-31
NZ510544A (en) 2003-04-29
AU773697B2 (en) 2004-06-03
SI1800692T1 (sl) 2011-05-31
DK1140166T3 (da) 2007-07-02
CA2718376A1 (en) 2000-06-22
HK1110769A1 (en) 2008-07-25
SI1140166T1 (sl) 2007-08-31
CA2342609A1 (en) 2000-06-22
ATE496630T1 (de) 2011-02-15
DE69943170D1 (de) 2011-03-10
ES2284285T3 (es) 2007-11-01
CY1111372T1 (el) 2015-08-05
PT1140166E (pt) 2007-06-27
ATE359817T1 (de) 2007-05-15
DE69935866T2 (de) 2008-01-10
WO2000035482A3 (en) 2000-10-26
PT1800692E (pt) 2011-03-31
DK1800692T3 (da) 2011-03-28
ES2358540T3 (es) 2011-05-11
AU2845100A (en) 2000-07-03
EP1140166A2 (en) 2001-10-10
EP1140166B1 (en) 2007-04-18
WO2000035482A2 (en) 2000-06-22
CA2342609C (en) 2010-11-16
JP2002532436A (ja) 2002-10-02
EP1800692A1 (en) 2007-06-27
US6017537A (en) 2000-01-25
EP1800692B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
CY1106635T1 (el) Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
NO20011282L (no) Nytt influensavirusvaksinepreparat
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
ES2002490A6 (es) Un metodo de preparar un virus recombinante
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
DK47286A (da) Hundeparvovirus-vacciner
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE329615T1 (de) Borrelia burgdorferi bacterin
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
BR0013574A (pt) Antìgeno vacina de moraxella
ATE374622T1 (de) Genetische impstoffe mit adjuvans
DK0627006T3 (da) Hybrid-DNA, der koder for en underenhed af et bakterietoxin med et hæmolysin.
CY1116907T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων
CY1110086T1 (el) Πεπτιδια καρκινικου αντιγονου προερχομενα απο wt1